Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Lehner VDC |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Pre-Clinical NHP |
| Species: | Rhesus macaque |
| Stage: | Assays Completed |
| Study Start Date: | 2009-01-08 |
| Study Made Public: | 2012-03-28 |
Title
Lehner_Thorstensson_Allovac
Description
CAVD 239 (CAVIMC-015) is a non-human primate challenge study comparing 5 different peptide/protein/adjuvant regimens including HLA-antigens and/or HIV-1 gp120/SIVp27 antigens.
Sign in to see full information about this study and to download study data.
Products
HIV-1 gp140 Titermax SIV-Gag p27 HSP 70 MHC Class I and II SHIV-SF162P4 NoneIntegrated data
NAb
Non-integrated data
No non-integrated data is available for this study.